WHO Approval of Chinese Vaccines Can Increase Global Supply

By GAUDEN GALEA

THE decision announced on May 7 by the World Health Organization in Geneva to grant emergency use listing （EUL） to a COVID-19 vaccine manufactured in China represents a milestone moment. The successful EUL application is built on years of training and research by Chinese scientists， as well as decades of investment， coordinated efforts， and reform on the part of the government， national regulators， and the manufacturers themselves. We look forward to such recognition of more Chinese-produced vaccines in the future， and not only for COVID-19. This marks a new chapter in China’s role in global public goods supply in health， building on its R&D capability and manufacturing capacity， as well as its commitment to contribute substantially to global health.

The highly anticipated WHO EUL of the vaccine communicates both at home and abroad that the vaccine is of assured quality， is safe for use， meets WHO’s requirements for efficacy， and will be an important tool in fighting the global pandemic which has now claimed over three million lives worldwide. At this point last year， we hoped – but could not be confident – that the world would have at least one effective vaccine against the completely new virus. It is a testament to the ingenuity and dedication of scientists and researchers in China and around the globe， and the resilience and power of humankind in fighting a common challenge， that the announcement adds to the five EULs already granted by WHO for COVID-19 vaccines， with another five still under active review.

These vaccines are a critically impor- tant part of the COVID-19 pandemic toolkit. In addition to contact tracing， testing， isolation or quarantine where needed， personal protective measures like masking and hand washing， or improved medical treatments， COVID-19 vaccines will help us put the pandemic behind us.

But that won’t happen until the vaccines are made available to everyone， everywhere.

At home in China， there is an urgent need for us to press ahead with the unfinished business of the response. We need to continue to adhere to the public health measures （hygiene， physical distancing， and masks） that remain essential in a vaccinated world while the pandemic continues around us. At the same time， we need to overcome any COVID-19 complacency and commit to be vaccinated. The success of the pandemic response in 2020 and earlier this year has meant that， in China， we now live mostly unrestricted in our daily routines. That may make some of us think that getting the vaccine is something we will do eventually， but there is no rush. The reality， however， is the sooner we are all vaccinated， the sooner we can look forward to a day when trade and tourism can resume. Each one of us has a part to play in shortening the length of time between now and when COVID is truly a thing of the past.

Around the world， more than a billion vaccine doses have been administered. Among those， 100 million were administered in April – but only one percent （one million doses） went to low-income countries. The rest – 99 million doses – went to high- and middle-income countries. Collectively， we need to do more to ensure COVID-19 vaccines are made available as part of a coordinated， multilateral response via the global COVAX facility established last year. Uncoordinated bilateral deals， while well-intentioned， have made this more difficult and resulted in a situation where， at the start of May， 14 countries had still not received any vaccines at all. Working through established multilateral systems like COVAX remains our best opportunity for ensuring equitable access to the current supply.

In addition， it is imperative that we increase global supply. WHO Director General Tedros has called on vaccine producing countries to accelerate technology transfer， either through voluntary licensing， sharing of licenses through the COVID-19 technology access pool， or by waiving intellectual property rights through a WTO agreement. We welcome recent comments by Chinese manufacturers that they are undertaking efforts toward technology transfer in other countries and encourage rapid acceleration of these commitments to expand local supply.

Today we take a moment to recognize an important advance in the development of China’s global vaccine contributions. Tomorrow， we will redouble our efforts to stamp out the virus at home and abroad， by working collectively to ensure equitable access to these lifesaving vaccines.

One vaccine has received EUL， but we know that there are over 15 additional COVID-19 vaccines in advanced development in China. Today’s milestone achievement should spur other manufacturers to pursue this route and add to the global vaccine arsenal. It should also encourage an even greater contribution from China to global supply and vaccine equity.